home contact company.overview news sitemap print


NMI-TT Contact Person

Markwiesenstr. 55
72770 Reutlingen

Ion Channel


page: 1 of 10 | items: 1 to 3 | next

Press Release: DigiWest multiplex protein profiling technology published in Nature Communications
Reutlingen, Germany, September 26, 2016 – The Natural and Medical Sciences Institute at the University of T├╝bingen (NMI), a private research foundation, and its contract research provider NMI TT Pharmaservices today announced the publication of their proprietary DigiWest┬« protein profiling method in the peer-reviewed scientific journal Nature Communications. [more...]

6th Global Reverse Phase Protein Array Workshop
Come to Reutlingen, and hear about the latest advances in Reverse Phase Protein Arrays (RPPAs) and their application for biomarker research.

Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for treatment of Fragile X Syndrome

Cambridge/UK and Berlin/Germany, May 2, 2016 – Sentinel Oncology
and NMI TT Pharmaservices today announced that they have received grant funding for the development of a companion diagnostic to compliment the ongoing drug development activities within Sentinel Oncology for the treatment of the Fragile X Syndrome (FXS), a genetically inherited orphan disease that manifests itself in intellectual disability, for which no treatments are currently available. [more...]



NMI TT a business unit of NMI